Country
Clinical Trials in Niger
Studies with at least one site in Niger. Open a trial for its sites in Niger, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 5Mortality, Antimicrobial Resistance
Azithromycin for Child Survival in Niger II
Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR).
- Trial name
- AVENIR II (NCT06358872)
- Testing
- Azithromycin for Oral Suspension
- Where
- Niger
- Volunteers
- 3,300,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Integrating the Guardian Spatial Emanator Within AVENIR II
This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger.
- Trial name
- GUARD-AV (NCT07712263)
- Testing
- Spatial Emanator
- Where
- Niger
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malnutrition Severe, Vaccination
OptiMAx Will Test Whether SQ-LNS Incentivises Vaccination Uptake in Rural Chad and Niger, With a Cost Effectiveness Analysis. It Will Also Look at Whether Having Received SQ-LNS Before Becoming Malnourished Leads to Better Outcomes for Children Treated Under the OptiMA Protocol.
Malnutrition and infectious disease form a vicious circle, posing a double threat to vulnerable children in low- and middle-income countries.
- Trial name
- OptiMAx (NCT07592260)
- Testing
- small quantity lipid-based supplement (SQ-LNS)
- Where
- 2 sites in Chad, Niger
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Alliance for International Medical Action
Pediatric Cancer
Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa
The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group.
- Trial name
- RFAOP (NCT03803735)
- Where
- 14 sites in Burkina Faso, Cameroon and 10 more
- Volunteers
- 10,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent…
- Conditions
- Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs
- Trial name
- Tri-Do-Re (NCT04260477)
- Testing
- 6EH³R³Z, 6EHRZ
- Where
- Niger
- Volunteers
- 370 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Completed, with results posted
All –Mortality, Resistance Bacterial
Azithromycin for Child Survival in Niger: Mortality and Resistance Trial
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include…
- Conditions
- Mortality, Resistance Bacterial, Child, Only
- Trial name
- AVENIR (NCT04224987)
- Testing
- Azithromycin
- Where
- Niger
- Volunteers
- 864,493 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Azithromycin Reduction to Reach Elimination of Trachoma
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger.
- Trial name
- ARRET (NCT04185402)
- Testing
- Azithromycin
- Where
- Niger
- Volunteers
- 3,931 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pneumococcal Carriage
Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)
The aim of this study is to assess the impact of a mass campaign with a single, fractional dose of Pneumosil®, a PCV10, on VT carriage.
- Trial name
- fPCV (NCT05175014)
- Testing
- PCV10 full dose, PCV10 fractional dose
- Where
- Niger
- Volunteers
- 44,618 people, healthy volunteers welcome
- Sponsor
- Epicentre
Childhood Mortality
Mortality Reduction After Oral Azithromycin: Mortality Study
Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality.
- Trial name
- MORDORIMort (NCT02047981)
- Testing
- Azithromycin
- Where
- 6 sites in United States, Malawi and 3 more
- Volunteers
- 190,238 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Childhood Mortality
Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality.
- Trial name
- MORDORIIMortY5 (NCT03338244)
- Testing
- Azithromycin
- Where
- 2 sites in United States, Niger
- Volunteers
- 66,228 people
- Sponsor
- University of California, San Francisco